Progress of treatment of extranodal natural killer/T cell lymphoma
10.3760/cma.j.issn.1009-9921.2016.12.004
- VernacularTitle:结外NK／T细胞淋巴瘤研究进展
- Author:
Xiaotong LI
;
Lei FAN
;
Jianyong LI
- Keywords:
Extranodal natural killer / T cell lymphoma;
American Society of Hematology Annual Meeting
- From:
Journal of Leukemia & Lymphoma
2016;25(12):717-719
- CountryChina
- Language:Chinese
-
Abstract:
Extranodal natural killer/T cell lymphoma (ENKTL) is an EBV-associated and highly aggressive subtype of non-Hodgkin lymphoma. Most patients are distributed in Asia and South America, and advanced-stage patients have poor prognosis. Reports on research progress of ENKTL in the 58th American Society of Hematology Annual Meeting covered multiple respects which range from basic research to clinical prognosis and treatment: further study on pathogenesis of ENKTL is developing based on high-throughput sequence, and new prognostic index system can help to stratify patients more exactly; what's more, novel regimens make more benefits to the clinical efficacy and safety of ENKTL patients.
